Mepolizumab is currently approved for the treatment of eosinophilic granulomatosis with polyangiitis (EGPA) at a dose of 300mg. touchRESPIRATORY caught up with Dr. Ozge Can Bostan (Hacettepe University School of Medicine, Ankara, Turkey) to discuss the 1 year findings from her study investigating the sinonasal and respiratory outcomes of a low dose of mepolizumab (100 mg) in the treatment of EGPA.
The abstract ‘Sinonasal and respiratory outcomes of EGPA patients receiving 100 mg Mepolizumab in real-life clinical practice: 1-year follow up study.’ was presented at EAACI 2022, 1-3 July, 2022.
Questions
- Could you tell us a little about eosinophilic granulomatosis with polyangiitis (EGPA) and the unmet needs in its treatment? (0:19)
- What is the rationale for the use of mepolizumab in the treatment of people with EGPA? (1:20)
- What clinical evidence to date supports the use of mepolizumab in this indication? (2:00)
- Could you tell us a little about your real-world study and its findings at 1 year? (2:35)
- What has this study taught us about the optimal use of mepolizumab? (3:20)
Disclosures: Ozge Can Bostan has nothing to disclose in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the EAACI Hybrid Congress 2022.
